Clinical Trial Detail

NCT ID NCT03139747
Title UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

thyroid gland cancer

Therapies

Everolimus + Lenvatinib

Age Groups: adult senior

No variant requirements are available.